Navigating Aetna Ocrevus Prior Authorization

Efficiently managing Aetna Ocrevus prior authorization is critical for timely patient access to this essential therapy for multiple sclerosis.

For revenue cycle directors and prior authorization teams, navigating the complexities of specialty drug approvals can impact both patient care and financial outcomes. This guide outlines the specific considerations for obtaining Aetna prior authorization for Ocrevus, focusing on submission pathways, policy criteria, and key operational insights.

Understanding Ocrevus and Aetna's Medical Benefit PA

Ocrevus (ocrelizumab) is a monoclonal antibody prescribed for relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). As an infused biologic, Ocrevus typically falls under Aetna's medical benefit. This requires specific prior authorization processes distinct from pharmacy benefit medications, often involving detailed clinical documentation to establish medical necessity.

Aetna Prior Authorization Submission Channels for Ocrevus

For medical benefit prior authorizations, including Ocrevus, Aetna primarily utilizes the Availity provider portal for commercial and Medicare Advantage plans. Providers can also submit X12 278 transactions via clearinghouses, offering an electronic data interchange (EDI) option for eligible procedure categories. Understanding these pathways is key to selecting the most efficient submission method.

Key Aetna Policy and Criteria Considerations for Ocrevus

Clinical Policy Bulletins (CPBs): Aetna publishes medical necessity criteria for specialty drugs like Ocrevus within its public CPB library. Providers must consult the specific, current CPB for ocrelizumab to understand covered indications, dosage, and duration of therapy.
Medical Necessity Documentation: Approval hinges on comprehensive clinical documentation supporting the diagnosis of RMS or PPMS, previous treatment history, and rationale for Ocrevus per Aetna's criteria.
Step Therapy Requirements: Aetna's CPBs for multiple sclerosis therapies may outline step therapy protocols. Ensure documentation reflects adherence to, or appropriate exceptions for, any required preceding therapies.
Site-of-Service: For infused medications, Aetna's policies may include site-of-service criteria, influencing whether administration is covered in an outpatient hospital setting, infusion center, or home setting.

Turnaround Times and Regulatory Impact

Prior authorization decision timeframes for Aetna vary by line of business and state regulations. While commercial plans are subject to state-mandated minimums and NCQA Utilization Management accreditation standards (historically 15 calendar days for non-urgent pre-service decisions), Aetna's Medicare Advantage plans are directly impacted by CMS-0057-F. This rule mandates 72-hour decisions for standard and 24-hour for expedited PA requests for these lines of business.

Common Denial Reasons and Appeal Pathways for Ocrevus

Denials for Ocrevus prior authorizations often stem from insufficient documentation of medical necessity, failure to meet step therapy requirements, or off-label use without compendium support. Aetna communicates denial reasons via X12 835/277 transactions or portal status updates, utilizing CARC and RARC codes. Should a denial occur, Aetna's appeal process typically includes reconsideration, peer-to-peer review, and formal appeals. Expedited appeal pathways are available for urgent care needs, with timely-filing windows varying by line of business and state.

Klivira's Role in Streamlining Aetna Ocrevus PA

Klivira automates the submission and tracking of prior authorizations for specialty drugs like Ocrevus, integrating with EMRs and payer portals. Our platform connects directly with Aetna's Availity portal and supports X12 278 transactions, reducing manual effort and accelerating decision times for complex medical benefit PAs. This ensures your team can focus on patient care rather than administrative burdens.

Frequently asked questions

What are the primary submission channels for Aetna Ocrevus prior authorization?

For Ocrevus, typically managed under the medical benefit, primary submission channels for Aetna include the Availity provider portal for commercial and Medicare Advantage plans, as well as X12 278 transactions via clearinghouses for applicable procedure codes.

Where can I find Aetna's medical necessity criteria for Ocrevus?

Aetna publishes its medical necessity criteria, including those for specialty drugs like Ocrevus, within its public Clinical Policy Bulletins (CPBs) library. You should always reference the most current and specific CPB for ocrelizumab.

Does Aetna have step therapy requirements for Ocrevus?

Aetna's Clinical Policy Bulletins for multiple sclerosis therapies may include step therapy protocols. It is crucial to review the specific Ocrevus CPB to understand any applicable requirements and ensure your documentation addresses them.

What are common reasons for an Aetna Ocrevus prior authorization denial?

Common denial reasons for Ocrevus prior authorizations with Aetna include insufficient documentation of medical necessity, failure to meet outlined step therapy requirements, or instances of off-label use without adequate compendium support. Site-of-service mismatches can also lead to denials for infused medications.

How does CMS-0057-F impact Aetna Ocrevus prior authorizations?

CMS-0057-F directly impacts Aetna's Medicare Advantage plans, mandating specific decision timeframes of 72 hours for standard and 24 hours for expedited prior authorization requests. This rule will significantly influence the turnaround times for Ocrevus approvals in these lines of business.